Actively Recruiting
5-HT3 Receptor Antagonist (Ramosetron) vs Loperamide for the Treatment of Low Anterior Resection Syndrome(RALARS)
Led by Seoul National University Hospital · Updated on 2023-04-25
212
Participants Needed
1
Research Sites
505 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Safety \& Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) versus Loperamide for the Treatment of Low Anterior Resection Syndrome (RALLARS): Multicenter Randomized Controlled Trial
CONDITIONS
Official Title
5-HT3 Receptor Antagonist (Ramosetron) vs Loperamide for the Treatment of Low Anterior Resection Syndrome(RALARS)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of mid or low rectal cancer (anorectal verge less than 15 cm)
- Stage II or III rectal cancer
- Completed preoperative long-course chemoradiotherapy
- Underwent ileostomy repair
- Between 1 and 12 months after rectal cancer surgery without a stoma
- Between 1 and 6 months after ileostomy repair
- Experiencing major Low Anterior Resection Syndrome (LARS)
You will not qualify if you...
- Recurrent rectal cancer
- Stage IV rectal cancer
- Inflammatory bowel disease (IBD)
- Uncontrolled fecal incontinence or constipation before surgery
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Seoul National University Hospital
Seoul, Jongro-gu, South Korea, 03080
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here